Skip to main content
NCBI home page
The Canadian Veterinary Journal logoLink to The Canadian Veterinary Journal
. 1988 Jan;29(1):51–58.

Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium

Denis Archambault, Guylaine Morin
PMCID: PMC1680745  PMID: 17422948

Abstract

Several immunomodulator agents may influence the host immune system. Among them there are the adjuvants and the immunostimulant agents. In this paper, after a brief review of the mechanism of action of adjuvants, we have described the adjuvant and stimulant properties of muramyl-dipeptide, anaerobic corynebacteria and sodium diethyldithiocarbamate.

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abo-Shehada M. N., Herbert I. V. Investigation of effects of some immunoadjuvants and routes of antigen administration in raising antibodies in rabbits against metacestode cyst antigens of Taenia multiceps. J Immunol Methods. 1983 Jul 29;61(3):345–350. doi: 10.1016/0022-1759(83)90230-2. [DOI] [PubMed] [Google Scholar]
  2. Adlam C., Broughton E. S., Scott M. T. Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum. Nat New Biol. 1972 Feb 16;235(59):219–220. doi: 10.1038/newbio235219a0. [DOI] [PubMed] [Google Scholar]
  3. Allison A. C. Mode of action of immunological adjuvants. J Reticuloendothel Soc. 1979 Dec;26(Suppl):619–630. [PubMed] [Google Scholar]
  4. Audibert F., Chédid L., Lefrancier P., Choay J. Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell Immunol. 1976 Feb;21(2):243–249. doi: 10.1016/0008-8749(76)90053-8. [DOI] [PubMed] [Google Scholar]
  5. Bachrach H. L. New approaches to vaccines. Adv Vet Sci Comp Med. 1985;30:1–38. [PubMed] [Google Scholar]
  6. Bahr G. M., Chedid L. Immunological activities of muramyl peptides. Fed Proc. 1986 Oct;45(11):2541–2544. [PubMed] [Google Scholar]
  7. Binaghi R. A. Production of 7 S immunoglobulins in immunized guinea pigs. J Immunol. 1966 Aug;97(2):159–164. [PubMed] [Google Scholar]
  8. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol. 1980 Feb;39(2):426–434. [PMC free article] [PubMed] [Google Scholar]
  9. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol. 1980 Feb;39(2):435–441. [PMC free article] [PubMed] [Google Scholar]
  10. Bruley-Rosset M., Vergnon I., Renoux G. Influences of sodium diethyldithiocarbamate, DTC (imuthiolR) on T cell defective responses of aged BALB/c mice. Int J Immunopharmacol. 1986;8(3):287–297. doi: 10.1016/0192-0561(86)90110-4. [DOI] [PubMed] [Google Scholar]
  11. Carelli C., Ralamboranto L., Audibert F., Gaillard J., Briquelet N., Dray F., Fafeur V., Haour F., Chedid L. Immunological castration by a totally synthetic vaccine: modification of biological properties of LH-RH after conjugation to adjuvant-active muramyl peptide. Int J Immunopharmacol. 1985;7(2):215–224. doi: 10.1016/0192-0561(85)90029-3. [DOI] [PubMed] [Google Scholar]
  12. Cerutti I., Chany C. Coordinated therapeutic effects of immune modulators and interferon. Infect Immun. 1983 Nov;42(2):728–732. doi: 10.1128/iai.42.2.728-732.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chapes S. K., Haskill S. Role of Corynebacterium parvum in the activation of peritoneal macrophages. 1. Association between intracellular C. parvum and cytotoxic macrophages. Cell Immunol. 1982 Jun;70(1):65–75. doi: 10.1016/0008-8749(82)90133-2. [DOI] [PubMed] [Google Scholar]
  14. Chapes S. K., Haskill S. Role of Corynebacterium parvum in the activation of peritoneal macrophages. II. Identification of distinguishable anti-tumor activities by macrophage subpopulations. Cell Immunol. 1983 Feb 15;76(1):49–57. doi: 10.1016/0008-8749(83)90347-7. [DOI] [PubMed] [Google Scholar]
  15. Chedid L. A., Parant M. A., Audibert F. M., Riveau G. J., Parant F. J., Lederer E., Choay J. P., Lefrancier P. L. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun. 1982 Feb;35(2):417–424. doi: 10.1128/iai.35.2.417-424.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chedid L. Adjuvants of immunity. Ann Inst Pasteur Immunol. 1985 Nov-Dec;136D(3):283–291. doi: 10.1016/s0769-2625(85)80113-6. [DOI] [PubMed] [Google Scholar]
  17. Chedid L., Audibert F., Johnson A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy. 1978;25:63–105. [PubMed] [Google Scholar]
  18. Chedid L., Audibert F., Jolivet M. Role of muramyl peptides for the enhancement of synthetic vaccines. Dev Biol Stand. 1986;63:133–140. [PubMed] [Google Scholar]
  19. Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472–2475. doi: 10.1073/pnas.73.7.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chedid L., Carelli C., Audibert F. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc. 1979 Dec;26(Suppl):631–641. [PubMed] [Google Scholar]
  21. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Christie G. H., Bomford R. Mechanisms of macrophage activation by Corynebacterium parvum. I. In vitro experiments. Cell Immunol. 1975 May;17(1):141–149. doi: 10.1016/s0008-8749(75)80014-1. [DOI] [PubMed] [Google Scholar]
  23. Clark I. A., Cox F. E., Allison A. C. Protection of mice against Babesia spp. and Plasmodium spp. with killed Corynebacterium parvum. Parasitology. 1977 Feb;74(1):9–18. doi: 10.1017/s003118200004748x. [DOI] [PubMed] [Google Scholar]
  24. Cohen D. A., Bubel H. C. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages. J Reticuloendothel Soc. 1983 Jan;33(1):35–46. [PubMed] [Google Scholar]
  25. Cone R. E., Johnson A. G. Regulation of the immune system by synthetic polynucleotides. 3. Action on antigen-reactive cells of thymic origin. J Exp Med. 1971 Mar 1;133(3):665–676. doi: 10.1084/jem.133.3.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Cullen R. T., Ghaffar A. Possible mechanisms underlying the induction of cytotoxic macrophages by Corynebacterium parvum: in vitro induction of cytotoxicity in normal macrophages by immune lymphocytes. J Reticuloendothel Soc. 1978 Oct;24(4):339–349. [PubMed] [Google Scholar]
  27. Damais C., Riveau G., Parant M., Gerota J., Chedid L. Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol. 1982;4(5):451–462. doi: 10.1016/0192-0561(82)90020-0. [DOI] [PubMed] [Google Scholar]
  28. Dinarello C. A., Krueger J. M. Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. Fed Proc. 1986 Oct;45(11):2545–2548. [PubMed] [Google Scholar]
  29. Drews J. Immunostimulation. Clinical and experimental perspectives. Klin Wochenschr. 1984 Mar 15;62(6):254–264. doi: 10.1007/BF01721886. [DOI] [PubMed] [Google Scholar]
  30. Edelman R. Vaccine adjuvants. Rev Infect Dis. 1980 May-Jun;2(3):370–383. doi: 10.1093/clinids/2.3.370. [DOI] [PubMed] [Google Scholar]
  31. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  32. Ferguson T. A., Krieger N. J., Pesce A., Michael J. G. Enhancement of antigen-specific suppression by muramyl dipeptide. Infect Immun. 1983 Feb;39(2):800–806. doi: 10.1128/iai.39.2.800-806.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Fevrier M., Birrien J. L., Leclerc C., Chedid L., Liacopoulos P. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol. 1978 Aug;8(8):558–562. doi: 10.1002/eji.1830080804. [DOI] [PubMed] [Google Scholar]
  34. Ford R. B. Biological response modifiers in the management of viral infection. Vet Clin North Am Small Anim Pract. 1986 Nov;16(6):1191–1204. doi: 10.1016/s0195-5616(86)50137-6. [DOI] [PubMed] [Google Scholar]
  35. Galelli A., Chedid L. Induction of colony-stimulating activity (CSA) by a synthetic muramyl peptide (MDP): synergism with LPS and activity in C3H/HeJ mice and in endotoxin-tolerized mice. J Immunol. 1986 Nov 15;137(10):3211–3215. [PubMed] [Google Scholar]
  36. Galelli A., Chedid L. Modulation of myelopoiesis in vivo by synthetic adjuvant-active muramyl peptides: induction of colony-stimulating activity and stimulation of stem cell proliferation. Infect Immun. 1983 Dec;42(3):1081–1085. doi: 10.1128/iai.42.3.1081-1085.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Glasgow L. A., Fischbach J., Bryant S. M., Kern E. R. Immunomodulation of host resistance to experimental viral infections in mice: effects of Corynebacterium acnes, Corynebacterium parvum, and Bacille calmette-guérin. J Infect Dis. 1977 May;135(5):763–770. doi: 10.1093/infdis/135.5.763. [DOI] [PubMed] [Google Scholar]
  38. Gorhe D. S. Inhibition of multiplication of foot and mouth disease virus in adult mice pretreated with Freund's complete adjuvant. Nature. 1967 Dec 23;216(5121):1242–1244. doi: 10.1038/2161242a0. [DOI] [PubMed] [Google Scholar]
  39. Hilgers L. A., Snippe H., Jansze M., Willers J. M. Effect of in vivo administration of different adjuvants on the in vitro candidacidal activity of mouse peritoneal cells. Cell Immunol. 1985 Jan;90(1):14–23. doi: 10.1016/0008-8749(85)90164-9. [DOI] [PubMed] [Google Scholar]
  40. Hirt H. M., Schwenteck M., Becker H., Kirchner H. Interferon production and lymphocyte stimulation in human leucocyte cultures stimulated by Corynebacterium parvum. Clin Exp Immunol. 1978 Jun;32(3):471–476. [PMC free article] [PubMed] [Google Scholar]
  41. Ikeda S., Negishi T., Nishimura C. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Antiviral Res. 1985 Aug;5(4):207–215. doi: 10.1016/0166-3542(85)90025-7. [DOI] [PubMed] [Google Scholar]
  42. Juy D., Chedid L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A. 1975 Oct;72(10):4105–4109. doi: 10.1073/pnas.72.10.4105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kirchner H., Holden H. T., Herberman Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol. 1975 Nov;115(5):1212–1216. [PubMed] [Google Scholar]
  44. Kotani S., Watanabe Y., Kinoshita F., Morisaki I., Kato K. The effect of replacement of L-alanine residue by glycine, L-serine or D-alanine in an N-acetylmuramyl-L-alanyl-D-isoglutamine on immunoadjuvancies of molecules. Biken J. 1977 Jun;20(2):39–45. [PubMed] [Google Scholar]
  45. Kotani S., Watanabe Y., Kinoshita F., Shimono T., Morisaki I. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. Biken J. 1975 Jun;18(2):105–111. [PubMed] [Google Scholar]
  46. Leclerc C., Bahr G. M., Chedid L. Marked enhancement of macrophage activation induced by synthetic muramyl dipeptide (MDP) conjugate using monoclonal anti-MDP antibodies. Cell Immunol. 1984 Jul;86(2):269–277. doi: 10.1016/0008-8749(84)90381-2. [DOI] [PubMed] [Google Scholar]
  47. Leclerc C., Bourgeois E., Chedid L. Demonstration of muramyl dipeptide (MDP)-induced T suppressor cells responsible for MDP immunosuppressive activity. Eur J Immunol. 1982 Mar;12(3):249–252. doi: 10.1002/eji.1830120316. [DOI] [PubMed] [Google Scholar]
  48. Lesavre P., Bach J. F. Place de l'immunostimulation dans la therapeutique anti-infectieuse. Comp Immunol Microbiol Infect Dis. 1980;3(4):391–406. doi: 10.1016/0147-9571(80)90016-8. [DOI] [PubMed] [Google Scholar]
  49. Lowy I., Theze J., Chedid L. Stimulation of the in vivo dinitrophenyl antibody response to the DNP conjugate of L-glutamic acid60-L-alanine30-L-Tyrosine10 (GAT) polymer by a synthetic adjuvant, muramyl dipeptide (MDP): target cells for adjuvant activity and isotypic pattern of MDP-stimulated response. J Immunol. 1980 Jan;124(1):100–104. [PubMed] [Google Scholar]
  50. Milas L., Scott M. T. Antitumor activity of Corynebacterium parvum. Adv Cancer Res. 1978;26:257–306. doi: 10.1016/s0065-230x(08)60090-1. [DOI] [PubMed] [Google Scholar]
  51. Milisauskas V. K., Cudkowicz G., Nakamura I. Cellular suppression of murine ADCC and NK activities induced by Corynebacterium parvum. Cancer Immunol Immunother. 1983;15(2):149–154. doi: 10.1007/BF00199707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Morahan P. S., Dempsey W. L., Volkman A., Connor J. Antimicrobial activity of various immunomodulators: independence from normal levels of circulating monocytes and natural killer cells. Infect Immun. 1986 Jan;51(1):87–93. doi: 10.1128/iai.51.1.87-93.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Murray M., Morrison W. I. Non-specific induction of increased resistance in mice to Trypanosoma congolense and Trypanosoma brucei by immunostimulants. Parasitology. 1979 Dec;79(3):349–366. doi: 10.1017/s0031182000053750. [DOI] [PubMed] [Google Scholar]
  54. Nagoya T., Kobayashi F., Nomoto K. Immunological properties of Propionibacterium acnes. I. Potentiation and Suppression on antibody response to sheep and hamster erythrocytes in mice. Microbiol Immunol. 1977;21(1):33–44. doi: 10.1111/j.1348-0421.1977.tb02805.x. [DOI] [PubMed] [Google Scholar]
  55. Nasrallah A. G., Gallagher M. T., Priest E. L., Trentin J. J. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity. Cancer Res. 1980 Nov;40(11):4159–4164. [PubMed] [Google Scholar]
  56. Neifeld J. P., Terz J. J., Kaplan A. M., Lawrence W., Jr Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx. J Surg Oncol. 1985 Feb;28(2):137–145. doi: 10.1002/jso.2930280215. [DOI] [PubMed] [Google Scholar]
  57. Neumann C., Macher E., Sorg C. Interferon production by Corynebacterium parvum and BCG-activated murine spleen macrophages. Immunobiology. 1980 Apr;157(1):12–23. doi: 10.1016/S0171-2985(80)80057-X. [DOI] [PubMed] [Google Scholar]
  58. Neveu P. J., Perdoux D., Lafleur L. In vivo enhancement of mitogen-induced lymphocyte DNA synthesis by sodium diethyl-dithiocarbamate (DTC). Int J Immunopharmacol. 1982;4(1):9–13. doi: 10.1016/0192-0561(82)90003-0. [DOI] [PubMed] [Google Scholar]
  59. Neveu P. J. The effects of thiol moiety of levamisole on both cellular and humoral immunity during the early response to a hapten-carrier complex. Clin Exp Immunol. 1978 Jun;32(3):419–422. [PMC free article] [PubMed] [Google Scholar]
  60. Neveu P. J., Vincendeau P. Sodium diethyl dithiocarbamate and the mononuclear phagocytic system in guinea pigs. Int Arch Allergy Appl Immunol. 1983;71(3):276–278. doi: 10.1159/000233403. [DOI] [PubMed] [Google Scholar]
  61. Ogawa T., Kotani S., Shimauchi H. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin. Methods Find Exp Clin Pharmacol. 1986 Feb;8(2):117–125. [PubMed] [Google Scholar]
  62. Oppenheim J. J., Togawa A., Chedid L., Mizel S. Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol. 1980 Mar 1;50(1):71–81. doi: 10.1016/0008-8749(80)90007-6. [DOI] [PubMed] [Google Scholar]
  63. Osada Y., Otani T., Sato M., Une T., Matsumoto K., Ogawa H. Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun. 1982 Dec;38(3):848–854. doi: 10.1128/iai.38.3.848-854.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Osebold J. W. Mechanisms of action by immunologic adjuvants. J Am Vet Med Assoc. 1982 Nov 15;181(10):983–987. [PubMed] [Google Scholar]
  65. Parant M., Chedid L. Stimulation of non-specific resistance to infections by synthetic immunoregulatory agents. Infection. 1985;13 (Suppl 2):S251–S255. doi: 10.1007/BF01644439. [DOI] [PubMed] [Google Scholar]
  66. Pompidou A., Duchet N., Cooper M. D., Mace B., Telvi L., Coutance F., Hadden J. W., Renoux G. The generation and regulation of human T lymphocytes by Imuthiol. Evidence from an in vitro differentiation induction system. Int J Immunopharmacol. 1985;7(4):561–566. doi: 10.1016/0192-0561(85)90077-3. [DOI] [PubMed] [Google Scholar]
  67. Renoux G., Biziere K., Renoux M., Guillaumin J. M. The production of T-cell-inducing factors in mice is controlled by the brain neocortex. Scand J Immunol. 1983 Jan;17(1):45–50. doi: 10.1111/j.1365-3083.1983.tb00764.x. [DOI] [PubMed] [Google Scholar]
  68. Renoux G., Bizière K., Renoux M., Guillaumin J. M. Le cortex cérébral règle les réponses immunes des souris. C R Seances Acad Sci D. 1980 Mar 17;290(11):719–722. [PubMed] [Google Scholar]
  69. Renoux G., Guillaumin J. M., Renoux M. Favorable influences of imuthiol on mouse reproduction and immune system of offspring. Am J Reprod Immunol Microbiol. 1985 Jul;8(3):101–106. doi: 10.1111/j.1600-0897.1985.tb00317.x. [DOI] [PubMed] [Google Scholar]
  70. Renoux G. Immunopharmacologie et pharmacologie du diethyldithiocarbamate (DTC). J Pharmacol. 1982;13 (Suppl 1):95–134. [PubMed] [Google Scholar]
  71. Renoux G., Renoux M. Administration of DTC gives evidence of a role of the thymus in the control and regulation of factors inducing thymocyte differentiation in the mouse. Thymus. 1980 Dec;2(3):139–146. [PubMed] [Google Scholar]
  72. Renoux G., Renoux M., Guillaumin J. M., Gouzien C. Differentiation and regulation of lymphocyte populations: evidence for immunopotentiator-induced T cell recruitment. J Immunopharmacol. 1979;1(3):415–422. doi: 10.3109/08923977909026383. [DOI] [PubMed] [Google Scholar]
  73. Renoux G., Renoux M. Immunopotentiation and anabolism induced by sodium diethyldithiocarbamate. J Immunopharmacol. 1979;1(2):247–267. doi: 10.3109/08923977909026375. [DOI] [PubMed] [Google Scholar]
  74. Renoux G., Renoux M. The effects of sodium diethyldithiocarbamate, azathioprine, cyclophosphamide, or hydrocortisone acetate administered alone or in association for 4 weeks on the immune responses of BALB/C mice. Clin Immunol Immunopathol. 1980 Jan;15(1):23–32. doi: 10.1016/0090-1229(80)90017-3. [DOI] [PubMed] [Google Scholar]
  75. Renoux G., Touraine J. L., Renoux M. Induction of differentiation of human null cells into T lymphocytes under the influence of serum of mice treated with sodium diethyldithiocarbamate. J Immunopharmacol. 1980;2(1):49–59. doi: 10.3109/08923978009026387. [DOI] [PubMed] [Google Scholar]
  76. Ribi E., Cantrell J. L., Takayama K., Qureshi N., Peterson J., Ribi H. O. Lipid A and immunotherapy. Rev Infect Dis. 1984 Jul-Aug;6(4):567–572. doi: 10.1093/clinids/6.4.567. [DOI] [PubMed] [Google Scholar]
  77. Roche A. C., Bailly P., Monsigny M. Macrophage activation by MDP bound to neoglycoproteins: metastasis eradication in mice. Invasion Metastasis. 1985;5(4):218–232. [PubMed] [Google Scholar]
  78. Rouse B. T. Liposomes as carriers of antigens as well as other molecules involved in immunity. J Am Vet Med Assoc. 1982 Nov 15;181(10):988–991. [PubMed] [Google Scholar]
  79. Sadler T. E., Castro J. E. The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases. Br J Surg. 1976 Apr;63(4):292–296. doi: 10.1002/bjs.1800630410. [DOI] [PubMed] [Google Scholar]
  80. Sawyer R. T., Moon R. J., Beneke E. S. Trapping and killing of Candida albicans by Corynebacterium parvum-activated livers. Infect Immun. 1981 May;32(2):945–950. doi: 10.1128/iai.32.2.945-950.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Scott M. T. Biological effects of the adjuvant Corynebacterium parvum. I. Inhibition of PHA, mixed lymphocyte and GVH reactivity. Cell Immunol. 1972 Nov;5(3):459–468. doi: 10.1016/0008-8749(72)90072-x. [DOI] [PubMed] [Google Scholar]
  82. Scott M. T. Depression of delayed-type hypersensitivity by Corynebacterium parvum: mandatory role of the spleen. Cell Immunol. 1974 Aug;13(2):251–263. doi: 10.1016/0008-8749(74)90243-3. [DOI] [PubMed] [Google Scholar]
  83. Shapira M., Jolivet M., Arnon R. A synthetic vaccine against influenza with built-in adjuvanticity. Int J Immunopharmacol. 1985;7(5):719–723. doi: 10.1016/0192-0561(85)90157-2. [DOI] [PubMed] [Google Scholar]
  84. Specter S., Friedman H., Chedid L. Dissociation between the adjuvant vs mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc Soc Exp Biol Med. 1977 Jul;155(3):349–352. doi: 10.3181/00379727-155-39804. [DOI] [PubMed] [Google Scholar]
  85. Stewart-Tull D. E. The immunological activities of bacterial peptidoglycans. Annu Rev Microbiol. 1980;34:311–340. doi: 10.1146/annurev.mi.34.100180.001523. [DOI] [PubMed] [Google Scholar]
  86. Stiffel C., Chalvet H., Mazurek C. Activité antitumorale de différentes doses de Corynebacterium parvum en fonction de l'age de la souris. Ann Inst Pasteur Immunol. 1985 Jul-Aug;136D(1):19–27. [PubMed] [Google Scholar]
  87. Sugimoto M., Germain R. N., Chedid L., Benacerraf B. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP). J Immunol. 1978 Mar;120(3):980–982. [PubMed] [Google Scholar]
  88. Sugiyama M., Epstein L. B. Effect of Corynebacterium parvum on human T-lymphocyte interferon production and T-lymphocyte proliferation in vitro. Cancer Res. 1978 Dec;38(12):4467–4473. [PubMed] [Google Scholar]
  89. Swartzberg J. E., Krahenbuhl J. L., Remington J. S. Dichotomy between macrophage activation and degree of protection against Listeria monocytogenes and Toxoplasma gondii in mice stimulated with Corynebacterium parvum. Infect Immun. 1975 Nov;12(5):1037–1043. doi: 10.1128/iai.12.5.1037-1043.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Symoens J., Rosenthal M. Levamisole in the modulation of the immune response: the current experimental and clinical state. J Reticuloendothel Soc. 1977 Mar;21(3):175–221. [PubMed] [Google Scholar]
  91. Tanaka A., Nagao S., Saito R., Kotani S., Kusumoto S., Shiba T. Correlation of stereochemically specific structure in muramyl dipeptide between macrophage activation and adjuvant activity. Biochem Biophys Res Commun. 1977 Jul 25;77(2):621–627. doi: 10.1016/s0006-291x(77)80024-7. [DOI] [PubMed] [Google Scholar]
  92. Tenu J. P., Lederer E., Petit J. F. Stimulation of thymocyte mitogenic protein secretion and of cytostatic activity of mouse peritoneal macrophages by trehalose dimycolate and muramyldipeptide. Eur J Immunol. 1980 Aug;10(8):647–653. doi: 10.1002/eji.1830100813. [DOI] [PubMed] [Google Scholar]
  93. Wahl S. M., Wahl L. M., McCarthy J. B., Chedid L., Mergenhagen S. E. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979 Jun;122(6):2226–2231. [PubMed] [Google Scholar]
  94. Warren H. S., Vogel F. R., Chedid L. A. Current status of immunological adjuvants. Annu Rev Immunol. 1986;4:369–388. doi: 10.1146/annurev.iy.04.040186.002101. [DOI] [PubMed] [Google Scholar]
  95. White R. G. The adjuvant effect of microbial products on the immune response. Annu Rev Microbiol. 1976;30:579–600. doi: 10.1146/annurev.mi.30.100176.003051. [DOI] [PubMed] [Google Scholar]

Articles from The Canadian Veterinary Journal are provided here courtesy of Canadian Veterinary Medical Association

RESOURCES